Navigation Links
ADVENTRX to Present Complete ANX-530 Pharmacokinetic Data at the 2008 American Association for Cancer Research Annual Meeting
Date:2/7/2008

SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), announced today that complete pharmacokinetic data from the Company's marketing-enabling bioequivalence clinical study of ANX-530 (vinorelbine emulsion) has been accepted for presentation at the 2008 American Association for Cancer Research (AACR) Annual Meeting, which takes place April 12 - 16, 2008 in San Diego, CA.

The poster presentation entitled "Pharmacokinetic equivalence observed between an emulsion formulation of vinorelbine (ANX-530) and vinorelbine solution in a clinical study of patients with advanced cancer," is scheduled to be presented on April 13, 2008.

ADVENTRX recently completed a marketing-enabling bioequivalence clinical study of ANX-530. The primary endpoint in the study was met, with pharmacokinetic equivalence observed between ANX-530 and the reference drug Navelbine(R). Furthermore, ANX-530 demonstrated a statistically significant reduction in injection site reactions when compared to Navelbine. Presentation of complete safety results including injection site reactions, have been submitted for presentation at an upcoming oncology conference. ADVENTRX intends to submit to the U.S. Food and Drug Administration (FDA) a Section 505(b)(2) New Drug Application (NDA) for ANX-530 in the fourth quarter of 2008.

About ANX-530 (vinorelbine emulsion)

ANX-530 is designed to reduce the incidence and severity of injection site reactions from intravenous delivery of vinorelbine tartrate. Vinorelbine tartrate works by disrupting microtubule formation and is a member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is indicated as a single agent or in combination with cisplatin for treatment of advanced
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Consolidation of Clinical and Management Positions
2. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
3. ADVENTRX Appoints Vice President of Commercialization
4. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
5. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
8. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
9. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
10. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled a ... EST (11am PST), “Natural Language Processing: Converting Raw Data ... can turn raw, heterogeneous data into actionable knowledge to ... webinar will last approximately one hour. , Synopsis: Big ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... MITI ) ("Micromet" or the "Company"), a ... of cancer,inflammation and autoimmune diseases, today announced that ... appointed Dr. Peter Johann, a,current member of the ... Company,s,audit committee. The appointment fills the vacancy left ...
... ALTO, Calif., Sept. 15 Varian, Inc.,(NasdaqGS: VARI) ... promoted,Sean M. Wirtjes, Vice President and Controller, to ... September 15, 2008. Wirtjes,assumes the Treasurer position from ... Vice President and Chief Financial Officer., The ...
... Inc.,(Amex: PIP ) a biodefense company ... countermeasures against chemical and,biological threats, announced today ... of Health and Human Services (DHHS) that ... anthrax vaccine,SparVax(TM), has completed a comprehensive technical ...
Cached Biology Technology:Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 2Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 3Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule 4Varian, Inc. Board of Directors Makes Officer Changes 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 2PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 3PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration 4
(Date:4/23/2014)... release is available in French and German . ... or female? In humans and other mammals, the difference between sexes ... It is present only in males, where the two sexual chromosomes ... the Y is ultimately responsible for all the morphological and physiological ... been the case. A very long time ago, the X and ...
(Date:4/23/2014)... Huntington,s disease, most in their mid-thirties and forties, ... behavioral decline within two decades. "Mutant" protein clusters, ... disease, have been the primary focus of therapies ... new research from Prof. Gerardo Lederkremer and Dr. ... Cell Research and Immunology, in collaboration with Prof. ...
(Date:4/23/2014)... A team of researchers in Korea who ... brains of nonhuman primates and assessed cell survival ... that the hNSCs had differentiated into neurons at ... The study will be published in a future ... currently freely available on-line as an unedited early ...
Breaking Biology News(10 mins):Male or female? 2Male or female? 3On the defensive 2On the defensive 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... Biology in the College of Arts and Science at ... 2011 Fitch Award for Excellence in Herpetology from the ... individuals who have demonstrated long-term excellence in the study ... of amphibian ecology and wetland conservation, Semlitsch is well-known ...
... When an animal gets too hot or too cold, or feels ... where it,s cooler or hotter, or to the nearest place where ... life? What can a plant do under similar circumstances? ... move to a more favorable spot. Yet they do respond ...
... TREW Marketing , a full-service firm focused on the ... for Engineers , a free guidebook for ... Available for download on TREW Marketing,s website , the ... and outlines the firm,s proven process to grow awareness ...
Cached Biology News:Ray Semlitsch receives 2011 Fitch Award for Excellence in Herpetology 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 2Plant biologists dissect genetic mechanism enabling plants to overcome environmental challenge 3TREW Marketing Introduces Smart Marketing for Engineers, a Free Guidebook for Small Businesses Targeting Technical Audiences 2
The 50 ml Magnetic Separation Rack is designed to be used for small-scale separations using magnetic particles. ,Capacity: four 50 ml tubes. ,Magnets: Neodymium rare earth permanent magnets....
...
...
...
Biology Products: